CLAIMS

1. Use of abaloparatide, and $ZnCl_2$ in the manufacture of a medicament in the form of a transdermal patch for the treatment of osteoporosis whereby the patch is to be applied to a subject's thigh for about 5 minutes, the patch comprising: 300 µg of abaloparatide, and $ZnCl_2$, at a molar ratio of 2.2:1 of $ZnCl_2$:abaloparatide.

2. Use of abaloparatide, and $ZnCl_2$ in the manufacture of a medicament in the form of a transdermal patch for increasing bone mass density (BMD) in a subject in need thereof, whereby the patch is to be

administered daily to the subject's thigh for about 5 minutes, the patch comprising: 300 µg of abaloparatide, and $ZnCl_2$, at a molar ratio of 2.2:1 of $ZnCl_2$:abaloparatide,

wherein the subject is to achieve at least a 5% increase in BMD by 6 months.

3. Use of abaloparatide, and $ZnCl_2$ in the manufacture of a medicament in the form of a transdermal patch for transdermally delivering abaloparatide to a subject in an amount bioequivalent to subcutaneous injection of 80 mcg abaloparatide, whereby the patch is to be

administered daily to the subject's thigh for about 5 minutes, the patch comprising: 300 µg of abaloparatide, and $ZnCl_2$, at a molar ratio of 2.2:1 of $ZnCl_2$:abaloparatide,

wherein an amount of abaloparatide is transdermally delivered to the subject that is bioequivalent to subcutaneous injection of 80 mcg abaloparatide.

4. A once-daily transdermal system for the delivery of abaloparatide comprising:

a plurality of single-use transdermal patches, each loaded with about 300 µg of abaloparatide, and $ZnCl_2$ at a molar ratio of 2.2:1 of $ZnCl_2$:abaloparatide; and

instructions to administer one of said transdermal patches once daily to the thigh for about 5 minutes.

5. An aqueous formulation suitable for coating a transdermal patch wherein the aqueous formulation comprises 300 µg of abaloparatide, zinc at a molar ratio of 2.2:1 of Zn:abaloparatide.

6. The use, system or formulation according to any of the preceding claims, wherein the patch or formulation further comprises hydrochloric acid.

7. The use, system or formulation according to claim 6, wherein the mole ratio of hydrochloric acid to zinc chloride is at least 0.025.

8. The use, system or formulation according to any of the preceding claims, wherein the pH of the patch or formulation is about 4.5.

9. The use, system or formulation according to any of the preceding claims, wherein the pH of the patch or formulation is between about 4 and 4.75.